HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
Filed with ASX · · 2 pages · English
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- HEALEY ALS Platform Trial Regimen I expands to 240 participants
- HEALEY ALS Trial Regimen I Expands to 240 Participants
- Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
- Placement of Entitlement Offer Shortfall
- NUZ-001 Data Shows Multi-Pathway Protein Clearance
Later from Neurizon Therapeutics
- Neurizon executes long-term supply agreement with Elanco
- HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- Melbourne investor briefing presentation
- Appendix 4C & Quarterly Update
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics